Next 10 |
Study achieved its objective and demonstrated no evidence of tachyphylaxis, tolerance, or withdrawal with 180 mcg dose (highest approved dose) For each episode occurring over seven days, a reduction in agitation was observed and no serious adverse events were reported following treatmen...
NEW HAVEN, Conn., May 28, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that CEO Vimal Mehta, Ph.D., will present at the Jef...
NEW HAVEN, Conn., May 21, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that Rob Risinger, M.D., Chief Medical Officer ...
2024-05-09 11:58:09 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips BioXcel Therapeutics (NASDAQ: BTAI ) just reported results for the first quarter of 2024. BioXcel Therapeutics reported earnings per share of -87 cents. This was below the...
2024-05-09 09:53:09 ET BioXcel Therapeutics, Inc. (BTAI) Q1 2024 Results Earnings Conference Call May 9, 2024, 08:00 AM ET Company Participants Vimal Mehta - Chief Executive Officer and Founder Vincent O'Neill - Executive Vice President and Chief of Product Developme...
2024-05-09 07:07:42 ET More on BioXcel Therapeutics BioXcel Therapeutics, Inc. (BTAI) Q4 2023 Earnings Call Transcript BioXcel launches $25M direct offering of stock and warrants UBS cuts BioXcel to neutral; cites regulatory issues, financing Seeking Alpha...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
Advancing TRANQUILITY and SERENITY program plans for two pivotal Phase 3 trials to expand BXCL501 market potential in acute treatment of agitation Strengthened intellectual property portfolio for BXCL501 with grant of two new patents, in Japan and the U.S. Completed $25 million re...
2024-05-08 11:19:00 ET More on BioXcel Therapeutics BioXcel Therapeutics, Inc. (BTAI) Q4 2023 Earnings Call Transcript BioXcel launches $25M direct offering of stock and warrants UBS cuts BioXcel to neutral; cites regulatory issues, financing Seeking Alpha...
NEW HAVEN, Conn., April 25, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that it will release its first quarter 2024 financ...
News, Short Squeeze, Breakout and More Instantly...
BioXcel Therapeutics Inc. Company Name:
BTAI Stock Symbol:
NASDAQ Market:
BioXcel Therapeutics Inc. Website:
Study achieved its objective and demonstrated no evidence of tachyphylaxis, tolerance, or withdrawal with 180 mcg dose (highest approved dose) For each episode occurring over seven days, a reduction in agitation was observed and no serious adverse events were reported following treatmen...
NEW HAVEN, Conn., May 28, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that CEO Vimal Mehta, Ph.D., will present at the Jef...
NEW HAVEN, Conn., May 21, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that Rob Risinger, M.D., Chief Medical Officer ...